{
  "directed": true,
  "graph": {
    "annotation_list": {},
    "annotation_pattern": {
      "Species": "^\\d+$"
    },
    "annotation_url": {
      "Confidence": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno",
      "MeSHAnatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno"
    },
    "document_metadata": {
      "authors": "Sandra Spalek",
      "contact": "charles.hoyt@scai.fraunhofer.de",
      "copyright": "Copyright Â© 2019 Fraunhofer Institute SCAI, All rights reserved.",
      "description": "",
      "licenses": "CC BY 4.0",
      "name": "Anatabine Attenuates Tau Phosphorylation and Oligomerization in P301S Tau Transgenic Mice",
      "version": "1.0.0"
    },
    "namespace_pattern": {},
    "namespace_url": {
      "CHEBI": "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/chebi-names.belns",
      "CONSO": "https://raw.githubusercontent.com/pharmacome/conso/501ceccdc9a27d97edbdc48a89ebe8e1dd3626e9/export/conso-names.belns",
      "FPLX": "https://raw.githubusercontent.com/sorgerlab/famplex/d9ec0526c20795146a9a6aef17496efe1a36cac6/export/famplex.belns",
      "GO": "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/go-names.belns",
      "HGNC": "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc-names.belns",
      "MESH": "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/mesh-names.belns"
    },
    "namespaces_uncached": [],
    "path": "anatabine/paris2014.bel",
    "pybel_version": "0.13.2"
  },
  "links": [
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "reference": "10.4172/2168-975X.1000126",
        "type": "DOI"
      },
      "evidence": "During the time course of the treatment (40 days), 25% of Tg Tau P301S placebo mice became paralyzed (3 out of 12) whereas none (0 out of 11) in the anatabine treatment group developed paralysis during the study duration (Figure 1)",
      "key": "e4c0b85fab79ef744961413cd814b9313a8937d122c436dbeb14ee0028f4bd3102cd57f78a50bb90a3789bd88bb27dedd25329f0caa6e85eb655f18bc38af709",
      "line": 82,
      "relation": "decreases",
      "source": 0,
      "target": 17
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "reference": "10.4172/2168-975X.1000126",
        "type": "DOI"
      },
      "evidence": "Approximately 44 % (4 out of 9 non-paralyzed mice) of the placebo group (33 week-old mice) elicited an abnormal hind-limb extension reflex when suspended by the tail compared to 18% (2 out of 11) of Tg Tau P301S mice treated with anatabine (Figure 1).",
      "key": "21a9fbc0139adc3c8375595e0f3c916fb7ee7a38a50e9405b2702d3baed9c4206a7d78a55b528012737ef548e60dbf5ea84c9dcc637fc3b3056efc044b279e9a",
      "line": 90,
      "relation": "increases",
      "source": 0,
      "target": 4
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "reference": "10.4172/2168-975X.1000126",
        "type": "DOI"
      },
      "evidence": "In addition, Tg Tau P301S mice treated with anatabine showed an increased latency to fall (T-test, P<0.05) from an accelerating rotarod apparatus compared to Tg Tau P301S mice receiving regular drinking water (Figure 2) showing improved motor coordination.",
      "key": "b3628b42a891089e2b11a1b76671ef889bcc0220277cfd3283866e0711a42c5554678d3c9971a8ae1bc57c7900f8abc96a84b581b2f7680685cc07f08cf0243d",
      "line": 97,
      "relation": "increases",
      "source": 0,
      "target": 4
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "reference": "10.4172/2168-975X.1000126",
        "type": "DOI"
      },
      "evidence": "Tg Tau P301S mice treated with anatabine spent significantly more time (T-test, P<0.05) in the open arms of the elevated plus maze than placebo Tg Tau P301S mice (Figure 3).",
      "key": "9db5b795188b1fdae3fd23155ecbf0ca5e89afde0682a6b8767528a6883e6f2d585277c5c6e2887833fdeb95ef9f19f36d5df46dfe95258990559c9ac7489255",
      "line": 105,
      "relation": "decreases",
      "source": 0,
      "target": 16
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "reference": "10.4172/2168-975X.1000126",
        "type": "DOI"
      },
      "evidence": "Compared to age matched wild-type mice, 32 week-old Tg Tau P301S mice did not show spatial learning impairment in the RAWM (data not shown)",
      "key": "20d2201ef4855cb55be5b3a36884e5559eee87b1ae5c785cd1de53647b7e39f053ddfa37c12200f8d2edde71cfb94cd4dbde9ac36968737a548e67d9b8cf6ea7",
      "line": 113,
      "relation": "causesNoChange",
      "source": 0,
      "target": 15
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Brain": true,
          "Spinal Cord": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "reference": "10.4172/2168-975X.1000126",
        "type": "DOI"
      },
      "evidence": "No effect of the anatabine treatment was observed on tau expression (T-test, P>0.05) in Tg Tau P301S mice (Figure 4).",
      "key": "7829bbfd2d7d19bacfadfbd135454d67115bea41fdb097c71cb3efa42b85409d1b667e668ea790515a85ab081f1de034b2abf19a7c6886e10ab85f143aa93042",
      "line": 121,
      "relation": "causesNoChange",
      "source": 0,
      "target": 9
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Brain": true,
          "Spinal Cord": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "reference": "10.4172/2168-975X.1000126",
        "type": "DOI"
      },
      "evidence": "Moreover, a significant reduction in MC1-immunoreactivity (P<0.05) was observed in the detergent soluble and insoluble fractions of brain and spinal cord homogenates from Tg Tau P301S mice treated with anatabine showing that anatabine prevents the formation of pathological tau conformers (Figure 7).",
      "key": "e755af8a343456f5a589cb16c470738dc16e92c397f1557f9de2a29085238314672efc7c525309be68741027323e2efb132fa0632b911b3a14d5d2b04fc2724d",
      "line": 150,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 0,
      "target": 9
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Brain": true,
          "Spinal Cord": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "reference": "10.4172/2168-975X.1000126",
        "type": "DOI"
      },
      "evidence": "In both the detergent soluble and insoluble fractions of the brain and spinal cord homogenates of Tg Tau P301S mice, we found that tau phosphorylation was significantly reduced (T-tests, P<0.05) by the anatabine treatment for all the AD phosphorylated epitopes tested (Figure 6)",
      "key": "3fb75b54eefecb665e36982268506387a1c1f1d85a2d58eb57a73684095f6f8be12325e9908477d3b8ef05f5f846dfde45ef28c3df6ede2c6af1e3ae2d12a2fb",
      "line": 135,
      "relation": "decreases",
      "source": 0,
      "target": 12
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Brain": true,
          "Spinal Cord": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "reference": "10.4172/2168-975X.1000126",
        "type": "DOI"
      },
      "evidence": "In both the detergent soluble and insoluble fractions of the brain and spinal cord homogenates of Tg Tau P301S mice, we found that tau phosphorylation was significantly reduced (T-tests, P<0.05) by the anatabine treatment for all the AD phosphorylated epitopes tested (Figure 6)",
      "key": "188eda61f3c3153e0ca4c526a00ba3b55458063536bb9f127672cfedce289bb47863d1935e714efad396ea6d6a3726ff285619ca52d9590ea4c14a4fb3d65598",
      "line": 136,
      "relation": "decreases",
      "source": 0,
      "target": 10
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Brain": true,
          "Spinal Cord": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "reference": "10.4172/2168-975X.1000126",
        "type": "DOI"
      },
      "evidence": "In both the detergent soluble and insoluble fractions of the brain and spinal cord homogenates of Tg Tau P301S mice, we found that tau phosphorylation was significantly reduced (T-tests, P<0.05) by the anatabine treatment for all the AD phosphorylated epitopes tested (Figure 6)",
      "key": "f7b088de7beb169f9d8dd8a9e16875c2d4ee5588a48c6c436fb3551d0a8cf8a87cdcb85488bdbfef9215308d001db5ef5c450d6fd50526fdb2fdc0a29bac2f6a",
      "line": 137,
      "relation": "decreases",
      "source": 0,
      "target": 14
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Brain": true,
          "Spinal Cord": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "reference": "10.4172/2168-975X.1000126",
        "type": "DOI"
      },
      "evidence": "Moreover, a significant reduction in MC1-immunoreactivity (P<0.05) was observed in the detergent soluble and insoluble fractions of brain and spinal cord homogenates from Tg Tau P301S mice treated with anatabine showing that anatabine prevents the formation of pathological tau conformers (Figure 7).",
      "key": "1eb3fcfc316d90a5fbdf8d1b5c5a21bc90f82be81767df79e28ecbb25cda6c181999ac6e39bfd940bed9e1cb52ab526e1b4a6933f610808cf7e1fc4bb0bd09b2",
      "line": 148,
      "relation": "decreases",
      "source": 0,
      "target": 2
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Brain": true,
          "Spinal Cord": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "reference": "10.4172/2168-975X.1000126",
        "type": "DOI"
      },
      "evidence": "Additionally, a significant reduction (P<0.05) in tau oligomers levels (TOC1 immunopositive) was detected both in the brain and the spinal cord of Tg Tau P301S treated with anatabine using dot-blots (Figure 8).",
      "key": "653a11947799b9f81a867126c002c9e63e10c8863cdca5955f2a1001fc5d2e68f6b7af085cec427412cead3b0c2d336f3f4d4e763fa0bdd431712cda3e01c13a",
      "line": 159,
      "relation": "decreases",
      "source": 0,
      "target": 1
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Brain": true,
          "Spinal Cord": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "reference": "10.4172/2168-975X.1000126",
        "type": "DOI"
      },
      "evidence": "We observed that anatabine significantly prevented the formation of MC1-positive tau oligomers (Figure 9) by western-blots in both the brain and the spinal cord of Tg Tau P301S mice (T-tests, P<0.05) further confirming the data obtained with the dot-blots",
      "key": "af73b5f23c9d99e9ffd9151b7c1c7ad8b6bc14c03d251b5c97633c4d3b4f9d365eb1a612a04269add4b79838f9755c8981b401166eb81471fedcd0197e760415",
      "line": 168,
      "relation": "decreases",
      "source": 0,
      "target": 1
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Brain": true,
          "Spinal Cord": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "reference": "10.4172/2168-975X.1000126",
        "type": "DOI"
      },
      "evidence": "A significant reduction in Iba1 immunoreactivity was observed both in the brain (T-test, P<0.01) and spinal cord (T-test, P<0.01) homogenates of Tg Tau P301S mice treated with anatabine. Figure 10.",
      "key": "cfc7d38bc1651eaf38e66d9c4a56d46b518be2fa545ec3b8788c219a6377893db12d0998a83c94d09c84a8bc69ab61b45a4671b5ec1f6d2fd873c41f2fb9afad",
      "line": 178,
      "relation": "decreases",
      "source": 0,
      "target": 3
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "reference": "10.4172/2168-975X.1000126",
        "type": "DOI"
      },
      "evidence": "We found a significant increase in brain AKT Ser473 phosphorylation (T-test, P<0.001) and GSK3Î² Ser9 phosphorylation (T-test, P<0.001) in Tg Tau P301S mice treated with anatabine. Figure 11.",
      "key": "d96a4dbdaf4bd0b5bf93d189d1215cbc3707a03b539884dd1469ad844649c5a1f0cd333f7177f56118ed13d697e1d3ea890926787fb4cdd876ee583ed83a1e65",
      "line": 204,
      "relation": "increases",
      "source": 0,
      "target": 8
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "reference": "10.4172/2168-975X.1000126",
        "type": "DOI"
      },
      "evidence": "We found a significant increase in brain AKT Ser473 phosphorylation (T-test, P<0.001) and GSK3Î² Ser9 phosphorylation (T-test, P<0.001) in Tg Tau P301S mice treated with anatabine. Figure 11.",
      "key": "35a56b127ae4fd5df42e9d54377be32699f8ffbe560bde321033c364ba73a51b82af9a023340d40e3312c0742d9fbe7b5a0766154e39e50b23f6baae8bc3fdca",
      "line": 205,
      "relation": "increases",
      "source": 0,
      "target": 6
    },
    {
      "key": "0efa2343a1aab409feeae95a44c4251f713383a6e606f151efb4055e8f77a89d772738244ac3792bc5938f0fe885967c3489d8612cccddfd37a4a5dd7ed7c968",
      "relation": "hasVariant",
      "source": 9,
      "target": 12
    },
    {
      "key": "57f6dfc4cb18d002fb185a5f8ddb26897f5c0e93f59d9f1ee55374a026a04da6c975e40dd70e3f890ef9f9793c8b77bf916ea47533ecfee045a95797915ad8ba",
      "relation": "hasVariant",
      "source": 9,
      "target": 10
    },
    {
      "key": "43f3a05a562aea7d640aaac845125159fcfbdd06303b001b5cf1eec04af58dabda000353c3cf4551bae1aea91c8b1be6e3f2669e44287e4a25d0655b1d33aab4",
      "relation": "hasVariant",
      "source": 9,
      "target": 14
    },
    {
      "key": "09505215df0db1264915198df6f54ea647eb376b6ede05f22846b2d289a2907fa049769b8eb45a919e706a2eb7c7a96704537753eeb5e7c30a012888cd5296de",
      "relation": "hasVariant",
      "source": 9,
      "target": 11
    },
    {
      "key": "50403cc7ef5ce4172930d644a5740cda8918061439e7d529c0f888ba1b049a77a5339ec7d3482657b832429d9e62714c7fafa0d13366824ad8debfc61eaefc20",
      "relation": "hasVariant",
      "source": 9,
      "target": 13
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "reference": "10.4172/2168-975X.1000126",
        "type": "DOI"
      },
      "evidence": "Glycogen synthase 3Î² (GSK3Î²) is one of the main serine-threonine kinase responsible for tau phosphorylation and has been shown to affect tau phosphorylation at multiple AD relevant epitopes including Ser396, Ser404, Thr231 and Ser202",
      "key": "ab3b6f44bb41e8af4009adb2a2082bbb30544b86eee77390d1732ee74bf2107fe6626dcad574842f7724ec6f791a6e49e7c8347f420fa0e69f3432b40154a64b",
      "line": 185,
      "relation": "increases",
      "source": 7,
      "target": 11
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "reference": "10.4172/2168-975X.1000126",
        "type": "DOI"
      },
      "evidence": "Glycogen synthase 3Î² (GSK3Î²) is one of the main serine-threonine kinase responsible for tau phosphorylation and has been shown to affect tau phosphorylation at multiple AD relevant epitopes including Ser396, Ser404, Thr231 and Ser202",
      "key": "31872a87524d459a9e2a806ecd7f32a5ef327afcf5d497669f2b88f3f1103dbadab450d3711158d13ff83ae8b79c1048bb21e10461c4eeffb199617afb3249aa",
      "line": 186,
      "relation": "increases",
      "source": 7,
      "target": 13
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "reference": "10.4172/2168-975X.1000126",
        "type": "DOI"
      },
      "evidence": "Glycogen synthase 3Î² (GSK3Î²) is one of the main serine-threonine kinase responsible for tau phosphorylation and has been shown to affect tau phosphorylation at multiple AD relevant epitopes including Ser396, Ser404, Thr231 and Ser202",
      "key": "de08fc296ebe24ead740988563611fad57037673eb8c5c25797ff4e914abb46525fe3b06f52d189b94a95b7605309b73c86369d61d12f365f67ec6e4d51b47b0",
      "line": 187,
      "relation": "increases",
      "source": 7,
      "target": 14
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "reference": "10.4172/2168-975X.1000126",
        "type": "DOI"
      },
      "evidence": "Glycogen synthase 3Î² (GSK3Î²) is one of the main serine-threonine kinase responsible for tau phosphorylation and has been shown to affect tau phosphorylation at multiple AD relevant epitopes including Ser396, Ser404, Thr231 and Ser202",
      "key": "8ba6a93b5c2905819f2bd6f82e4b3258e55bb724c7a9a2b08d74dbf36e5daee975738d95e21d4628b8ead11534fa376134dcd6f613c589f7bcdeaa28bf298653",
      "line": 188,
      "relation": "increases",
      "source": 7,
      "target": 10
    },
    {
      "key": "c32cc4766e32f47c9607f6acfe2046eef85dae6a416e8f80bdf283a7b82d64714996d02bc368875e92e9cabfbc0ea8d565da15b5b80cee241c4e9d55b8920cea",
      "relation": "hasVariant",
      "source": 7,
      "target": 8
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "reference": "10.4172/2168-975X.1000126",
        "type": "DOI"
      },
      "evidence": "GSK3Î² is inactivated upon phosphorylation of Ser9 by protein kinase B (AKT) [41] whereas AKT phosphorylation at Ser473 results in AKT activation [42].",
      "key": "b2c3a03f8558bdc2b5e5575b4e09e1aacc7f2dccf4b87401daa3519b6ea068c09964c24e0c2231f2199909c7a08f7315caea914531cefbf37903f3f594ccf71c",
      "line": 194,
      "relation": "increases",
      "source": 5,
      "target": 8
    },
    {
      "key": "a1e9680e012ba6a69064a7671ba3c9b78ef9ba74a447bd4f3beaf3f83131af3f526c6797555e43aa1740e228e1c1db2421bc57f7b50721ff26325f84a235dc83",
      "relation": "hasVariant",
      "source": 5,
      "target": 6
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "reference": "10.4172/2168-975X.1000126",
        "type": "DOI"
      },
      "evidence": "GSK3Î² is inactivated upon phosphorylation of Ser9 by protein kinase B (AKT) [41] whereas AKT phosphorylation at Ser473 results in AKT activation [42].",
      "key": "12eb23c0bfbe26e9af9dc10e80ea0f50e08c2b3c630aa4f26c77f1623bffd4d4da1bee315ca129dd3a7a91d90314b5e19fe17abbbfd67d01c3b3ac03c3fdeea1",
      "line": 195,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 8,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "reference": "10.4172/2168-975X.1000126",
        "type": "DOI"
      },
      "evidence": "GSK3Î² is inactivated upon phosphorylation of Ser9 by protein kinase B (AKT) [41] whereas AKT phosphorylation at Ser473 results in AKT activation [42].",
      "key": "9f4573251f65c5801125ac94df58806eac723f85be6f09bded235c1daec765140cd61cd8049966828bed7c7e4e4b6a23659c1091dd2800afc4411ac3e41a9b0a",
      "line": 196,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 6,
      "target": 5
    }
  ],
  "multigraph": true,
  "nodes": [
    {
      "bel": "a(CHEBI:Anatabine)",
      "function": "Abundance",
      "id": "c77d4080804731f0ef07ad52ed2fbccdac5d02fb2620d8800d273e925feebcbf90b94a2399efeb42a91e65413550e0f713cd431329129e1cdd90329cae6b3ff6",
      "name": "Anatabine",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CONSO:\"Tau oligomers\")",
      "function": "Abundance",
      "id": "e9f53522ae92cf8d207d2d4c497e7586fed3ec49be71928b33d79c1df78ea4a46baccab2e07d8b8e99bbd19df0e69b0cdaf8fe0ce33b0c00993e202491f6a4bf",
      "name": "Tau oligomers",
      "namespace": "CONSO"
    },
    {
      "bel": "a(GO:\"neurofibrillary tangle\")",
      "function": "Abundance",
      "id": "3b50c674ff9633f408e5173562a06cf3a856abc95a8b034db8e940b464f1cea72df6f9fa9b7b02b5daf4eb86a37a155f203289451f7203a7b9c9e6c65313eadf",
      "name": "neurofibrillary tangle",
      "namespace": "GO"
    },
    {
      "bel": "bp(CONSO:Microgliosis)",
      "function": "BiologicalProcess",
      "id": "f54f3cbc8b86b86eea18dc5e3557624a4ce8badb61db4b8b7a1b1169b3db5d3dfc2cc91d03bbf96c3735beeb017ab0dad94da611e526ae016529b29ae0cdb722",
      "name": "Microgliosis",
      "namespace": "CONSO"
    },
    {
      "bel": "bp(GO:\"motor behavior\")",
      "function": "BiologicalProcess",
      "id": "181472b7f9a4b32696b87492619020f88bad9e24f439e97158614801e3fb1dda434c97b95c252baa65a43ba7d78eecfca26f91f6a5295d37b21e6873f04a73f6",
      "name": "motor behavior",
      "namespace": "GO"
    },
    {
      "bel": "p(FPLX:AKT)",
      "function": "Protein",
      "id": "3263678a1e320013081e7134e7e64e91b2c66e6fbd10dd7fe4fd282cf0cc3ba29b5cacb5e8eb0a8ac0a194f73b80dabcea5465b0fec5b044290b259ba889cef1",
      "name": "AKT",
      "namespace": "FPLX"
    },
    {
      "bel": "p(FPLX:AKT, pmod(Ph, Ser, 473))",
      "function": "Protein",
      "id": "a03427be792e54c499404cee2333f1af5ce254ac1009d1697dc3dff377487eaa81466198765c389ba5c3d317a2b2520654ead9baae6194a980d783e1df597c5b",
      "name": "AKT",
      "namespace": "FPLX",
      "variants": [
        {
          "code": "Ser",
          "identifier": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 473
        }
      ]
    },
    {
      "bel": "p(HGNC:GSK3B)",
      "function": "Protein",
      "id": "ac819ecac7786e3ea9b6906b318167c6a94fbbf428aff46f85083b83c50b9604342d39c1c36ff49c2cb3a04e491913164c3e4e7889dedd513b6196d9b0560c7c",
      "name": "GSK3B",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:GSK3B, pmod(Ph, Ser, 9))",
      "function": "Protein",
      "id": "8d7ebbd9db06bfd2384321706d086542b1139faa7e1e65bfa46266a43582c9b2d1475fad41e42b54b51c5c64fe134658d3b53c01964ce52c62163f2077b4e180",
      "name": "GSK3B",
      "namespace": "HGNC",
      "variants": [
        {
          "code": "Ser",
          "identifier": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 9
        }
      ]
    },
    {
      "bel": "p(HGNC:MAPT)",
      "function": "Protein",
      "id": "ad82d360f02888e890bb2d1f91d1dc020c21cebed2b4eed0193a58e6b396b5f0797d607568dea382c05ffe2a003537d10190b020739af8d51c8d7dbc19bf5ab1",
      "name": "MAPT",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:MAPT, pmod(Ph, Ser, 202))",
      "function": "Protein",
      "id": "49b56446b699c749fbb01c4560254bbf621f44bd52a02cb74e212fb0ef1b9b1616a31cfe6ca06023fee3689ef552a3e8fe71211987ebad4180c2d78535f4ad7a",
      "name": "MAPT",
      "namespace": "HGNC",
      "variants": [
        {
          "code": "Ser",
          "identifier": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 202
        }
      ]
    },
    {
      "bel": "p(HGNC:MAPT, pmod(Ph, Ser, 396))",
      "function": "Protein",
      "id": "233ebce30d7505cee42acc956f9d268e5b725e14853bd56fab3b87a93a4e0c8141a6fdec062d10e9c4924f6e13a61184600872c2f5080656e3ca27227eb4cb93",
      "name": "MAPT",
      "namespace": "HGNC",
      "variants": [
        {
          "code": "Ser",
          "identifier": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 396
        }
      ]
    },
    {
      "bel": "p(HGNC:MAPT, pmod(Ph, Ser, 396), pmod(Ph, Ser, 404))",
      "function": "Protein",
      "id": "39bce9d17a0e3ef84038e06e52460d0a74f6adb7a3bffaba4858b8ada9ad6cc683cfaf93b6bb11e329e2818937b3cb05c7bb618018d5bf2b718fbfcadcd03af5",
      "name": "MAPT",
      "namespace": "HGNC",
      "variants": [
        {
          "code": "Ser",
          "identifier": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 396
        },
        {
          "code": "Ser",
          "identifier": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 404
        }
      ]
    },
    {
      "bel": "p(HGNC:MAPT, pmod(Ph, Ser, 404))",
      "function": "Protein",
      "id": "a448f901ddc919f32d50fa5284355b4eb4ed52e9ebf8705052086706d728d8ebef0cc66616b7fbfda3aeffd49db6e41134fb39996aa9b996a73bce331de95767",
      "name": "MAPT",
      "namespace": "HGNC",
      "variants": [
        {
          "code": "Ser",
          "identifier": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 404
        }
      ]
    },
    {
      "bel": "p(HGNC:MAPT, pmod(Ph, Thr, 231))",
      "function": "Protein",
      "id": "fd67fbe5c0c0911e8bffaf415eb40748a781d8776f2e2cdf8a3f4f97f0f2f312aaa680c7b670dc27b11d220f0079b4d5e41cbcf095a568bc644b6e9eaefc50b3",
      "name": "MAPT",
      "namespace": "HGNC",
      "variants": [
        {
          "code": "Thr",
          "identifier": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 231
        }
      ]
    },
    {
      "bel": "path(MESH:\"Spatial Learning\")",
      "function": "Pathology",
      "id": "211fd251c25349853a592b788437a1aa0fe1602f377e94c9e69815a2a9f82bb978e86febde798f0201920212b625fdde1919ddc54014881c2255cb8c56ba7057",
      "name": "Spatial Learning",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:Anxiety)",
      "function": "Pathology",
      "id": "28f6f3390e4ae722f1c1298abe2059a3e03a8a2de93e506a747733d9e980ed28bb2feb1074ec430fda167d3f38e3c1d930e10c16e5e04f371938ce866caba0dc",
      "name": "Anxiety",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:Paralysis)",
      "function": "Pathology",
      "id": "9a9d3fac8791cc10e6306e8f54cbc46f2937c98c15723c882f44f4f64bd15e246328afe3554e3049a059dd5717d5cc28e4c6e24bb7b70287284843740ed31cb2",
      "name": "Paralysis",
      "namespace": "MESH"
    }
  ]
}